MONTPELLIER, France & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) (“the Company”), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces the completion of the reverse share split of the shares composing the Company’s share capital, as decided by the Chief Executive Officer on July 27th, 2026, following sub-delegation granted by the Board o